Brazil’s pharma potential
Brazil’s pharma market is the sixth largest market in the world in terms of sales revenue. Prescription drugs constitute half of sales, over-the-counter drugs take a 27% share, and generic drugs have the remaining 23%. The generic drug segment was the main driver behind the decade- long growth of pharma industry in Brazil, with its market sales tripling between 2009 and 2013.
Pharma exports from Brazil increased by around 41% between 2009 and 2013, touching a high of U.S. $1.516 billion (statistics courtesy EMIS report).
The valuation of Brazilian pharma markets has shown double digit growth in the past decade. Between 2012 and 2015, market valuations have increased from U.S. $25.2 billion to U.S. $35.3 billion (statistic courtesy statista.com).
Figures from a McKinsey report covering a decade-long historical period and future forecasts indicate that the Brazilian pharma market grew by 14.9% between 2005 and 2013, effectively tripling in valuation from BRL 20 billion to BRL 60 billion. Though a relative decline is observed in the growth rate from year 2014 onwards, it is still in a healthy and realistic range of 7%-10%, and is expected to be sustained through 2020.